MX2012001346A - Polipeptidos del factor ix modificados y usos de los mismos. - Google Patents

Polipeptidos del factor ix modificados y usos de los mismos.

Info

Publication number
MX2012001346A
MX2012001346A MX2012001346A MX2012001346A MX2012001346A MX 2012001346 A MX2012001346 A MX 2012001346A MX 2012001346 A MX2012001346 A MX 2012001346A MX 2012001346 A MX2012001346 A MX 2012001346A MX 2012001346 A MX2012001346 A MX 2012001346A
Authority
MX
Mexico
Prior art keywords
polypeptides
modified factor
factor
methods
relates
Prior art date
Application number
MX2012001346A
Other languages
English (en)
Spanish (es)
Inventor
Alan Brooks
Jun Wang
Xiaoqiao Jiang
Chandra Patel
Uwe Gritzan
Heiner Apeler
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43529743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012001346(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of MX2012001346A publication Critical patent/MX2012001346A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/644Coagulation factor IXa (3.4.21.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21022Coagulation factor IXa (3.4.21.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2012001346A 2009-07-31 2010-08-02 Polipeptidos del factor ix modificados y usos de los mismos. MX2012001346A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23055109P 2009-07-31 2009-07-31
PCT/US2010/044177 WO2011014890A1 (en) 2009-07-31 2010-08-02 Modified factor ix polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
MX2012001346A true MX2012001346A (es) 2012-02-17

Family

ID=43529743

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012001346A MX2012001346A (es) 2009-07-31 2010-08-02 Polipeptidos del factor ix modificados y usos de los mismos.

Country Status (21)

Country Link
US (1) US20120164130A1 (https=)
EP (1) EP2461821A4 (https=)
JP (1) JP2013500726A (https=)
KR (1) KR20120060209A (https=)
CN (1) CN102573890A (https=)
AU (1) AU2010278721A1 (https=)
BR (1) BR112012002072A2 (https=)
CA (1) CA2769258A1 (https=)
CL (1) CL2012000238A1 (https=)
CR (1) CR20120052A (https=)
CU (3) CU20120018A7 (https=)
DO (1) DOP2012000030A (https=)
EA (1) EA201290069A1 (https=)
EC (1) ECSP12011637A (https=)
GT (1) GT201200023A (https=)
IN (1) IN2012DN00908A (https=)
MX (1) MX2012001346A (https=)
PE (1) PE20121643A1 (https=)
SG (1) SG178119A1 (https=)
WO (1) WO2011014890A1 (https=)
ZA (1) ZA201200716B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2670618C (en) 2006-12-15 2016-10-04 Baxter International Inc. Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
EP4219547A3 (en) 2008-09-15 2023-10-18 uniQure biopharma B.V. Factor ix polypeptide mutant, its uses and a method for its production
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
CN102497884A (zh) 2009-07-27 2012-06-13 巴克斯特国际公司 凝血蛋白缀合物
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
KR101912335B1 (ko) 2009-07-27 2018-10-26 리폭센 테크놀로지즈 리미티드 비혈액 응고 단백질의 글리코폴리시알화
CN106110311A (zh) 2009-07-27 2016-11-16 百深公司 凝血蛋白缀合物
DK2598172T3 (da) * 2010-07-30 2019-07-01 Baxalta GmbH Nukleofile katalysatorer til oximforbindelse
HUE049352T2 (hu) 2010-12-22 2020-09-28 Baxalta GmbH Anyagok és módszerek egy vízoldható zsírsavszármazéknak egy fehérjéhez való konjugálására
CN104144950B (zh) * 2011-12-19 2017-09-05 迪乐方有限责任公司 含有重复的二糖单元的非抗凝的葡糖胺聚糖及其医药用途
BR112015011462A2 (pt) * 2012-11-20 2017-09-26 Univ North Carolina Chapel Hill processos e composições para proteínas fator ix modificadas
AU2014248617B2 (en) * 2013-03-13 2016-05-19 Ambrx, Inc. Modified canine leptin polypeptides
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
CA3034566A1 (en) 2016-07-27 2018-02-01 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor ix function
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
JP7578590B2 (ja) 2018-10-18 2024-11-06 インテリア セラピューティクス,インコーポレーテッド 第ix因子を発現するための組成物及び方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1520259A (zh) * 2001-04-25 2004-08-11 ���ݴ�ѧУ��ίԱ�� 利用球状载体将第八因子/第九因子进行肝脏基因转移治疗血友病的方法
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
AU2004296860B2 (en) * 2003-12-03 2010-04-22 Novo Nordisk A/S Glycopegylated factor IX
EP2423305A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof

Also Published As

Publication number Publication date
AU2010278721A1 (en) 2012-02-16
WO2011014890A1 (en) 2011-02-03
EP2461821A1 (en) 2012-06-13
CR20120052A (es) 2012-06-04
ZA201200716B (en) 2013-07-31
SG178119A1 (en) 2012-03-29
CN102573890A (zh) 2012-07-11
PE20121643A1 (es) 2012-11-25
KR20120060209A (ko) 2012-06-11
BR112012002072A2 (pt) 2016-11-08
CU20130057A7 (es) 2013-06-28
CU20120018A7 (es) 2012-06-21
IN2012DN00908A (https=) 2015-04-03
DOP2012000030A (es) 2012-02-29
CL2012000238A1 (es) 2012-10-05
CA2769258A1 (en) 2011-02-03
CU20130058A7 (es) 2013-06-28
ECSP12011637A (es) 2012-02-29
EP2461821A4 (en) 2013-07-03
JP2013500726A (ja) 2013-01-10
EA201290069A1 (ru) 2012-07-30
GT201200023A (es) 2014-01-27
US20120164130A1 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
MX2012001346A (es) Polipeptidos del factor ix modificados y usos de los mismos.
MY192475A (en) Modified factor ix polypeptides and uses thereof
WO2010034032A3 (en) Methods for preparing purified polypeptide compositions
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
MX2011007930A (es) Conjugados de insulina cristalina.
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
GEP20146056B (en) Acylated glucagon analogues
PH12013501136A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
UA104459C2 (uk) Антитіла проти fgfr3 і способи їх застосування
TN2012000126A1 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
TN2012000302A1 (en) Oxyntomodulin peptide analogue
WO2009137254A3 (en) Modified factor ix polypeptides and uses thereof
IN2012DN03883A (https=)
TN2012000479A1 (en) Fibronectin based scaffold domain proteins that bind pcsk9
MX2013004726A (es) Anticuerpos dkk1 y metodos de uso.
JO3635B1 (ar) مركبات صيدلانية صلبة وطرق لانتاجها
MX2015001083A (es) Polipeptidos de factor x modificados y usos de los mismos.
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
MX349948B (es) Proteínas inmunógenas y composiciones para el tratamiento y prevención de streptococcus agalactiae.
EP2663576A2 (en) Novel wnt compositions and therapeutic uses of such compositions
MX2010010457A (es) Vectores recombinantes de rinovirus.
MX2012013875A (es) Anticuerpos de union sparc en sangre periferica y usos de los mismos.
MY165075A (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
SG191060A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
MX2011008179A (es) Peptidos para vacuna.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal